BMJ open · 2017
Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: a cross-sectional analysis study using CPRD.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lacoin Laure, Lumley Matthew, Ridha Essra, Pereira Marta, McDonald Laura, Ramagopalan Sreeram, Lefèvre Cinira, Evans David, Halcox Julian P
Аннотация
OBJECTIVE: To describe the changes in prescribing of oral anticoagulant (AC) and antiplatelet (AP) agents in patients with non-valvular atrial fibrillation (NVAF) in the UK and to identify the characteristics associated with deviation from guideline-based recommendations.
DESIGN: Five cross-sectional analyses in a large retrospective population-based cohort study.
SETTING: General practices contributing data to the UK Clinical Practice Research Datalink.
PARTICIPANTS: The study included patients with a diagnosis of NVAF and eligible for anticoagulation (CHA2DS2-VASc score ≥2) on 1 April of 2012, 2013, 2014, 2015 and 1st January 2016.
RESULTS: The proportion of patients being treated with AC increased at each index date, showing an absolute rise of 16.7% over the study period. At the same time, the proportion of patients treated with an AP alone was reduced by half, showing an absolute decrease of 16.8%. The proportion of patients not receiving any antithrombotic (AT) treatment remained the same across the study period. A number of predictors were identified for AP alone or no treatment compared with AC treatment.
CONCLUSION: Major improvements in the AT management of patients with NVAF for stroke prevention in the UK were observed between April 2012 and January 2016. Despite this, nearly 20% of at-risk patients still received AP alone and over 15% were on no AT agents in January 2016.
DESIGN: Five cross-sectional analyses in a large retrospective population-based cohort study.
SETTING: General practices contributing data to the UK Clinical Practice Research Datalink.
PARTICIPANTS: The study included patients with a diagnosis of NVAF and eligible for anticoagulation (CHA2DS2-VASc score ≥2) on 1 April of 2012, 2013, 2014, 2015 and 1st January 2016.
RESULTS: The proportion of patients being treated with AC increased at each index date, showing an absolute rise of 16.7% over the study period. At the same time, the proportion of patients treated with an AP alone was reduced by half, showing an absolute decrease of 16.8%. The proportion of patients not receiving any antithrombotic (AT) treatment remained the same across the study period. A number of predictors were identified for AP alone or no treatment compared with AC treatment.
CONCLUSION: Major improvements in the AT management of patients with NVAF for stroke prevention in the UK were observed between April 2012 and January 2016. Despite this, nearly 20% of at-risk patients still received AP alone and over 15% were on no AT agents in January 2016.
Предметные рубрики MeSH
AgedAged, 80 and overAnticoagulantsAtrial FibrillationCross-Sectional StudiesDatabases, FactualDrug PrescriptionsFemaleGeneral PracticeGuideline AdherenceHeart FailureHumansHypertensionIschemic Attack, TransientMalePlatelet Aggregation InhibitorsPractice Guidelines as TopicPractice Patterns, Physicians'Retrospective StudiesStrokeUnited Kingdom